Menin inhibitors in AML
Revumenib, ziftomenib and other menin inhibitors in acute leukaemia.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 4, 11, 14, 10, 14.
All papers from the last 12 months
132 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Targeted therapy in KMT2Ar AMLHematology2026 DecPMID 41368921Review
- Maintenance therapy after allogeneic stem cell transplantation for relapse prevention in myeloid malignanciesCurr Opin Hematol2026 Nov 1PMID 42593279Review
- Synthesis and Clinical Application of Small-Molecule Drugs Approved by FDA in 2025Med Res Rev2026 NovPMID 42186184Review
- The nuclear oncoprotein SET is necessary for MLL/KMT2A mediated transcriptional activationExp Hematol2026 Oct 11PMID 42860218
- Menin inhibitors in acute leukemia: Advances and future directionsHematol Oncol Stem Cell Ther2026 Apr 1PMID 42854102Review
- Menin inhibition impairs metastatic colonization of Ewing sarcomaJCI Insight2026 Oct 8PMID 42690622
- Menin inhibition in pediatric UBTF-TD myelodysplastic syndrome: molecular rationale and clinical observationMol Cell Pediatr2026 Oct 6PMID 42836918
- Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH)Am J Hematol2026 Oct 4PMID 42830228Review
- Menin inhibitors unleash JUND-mediated resistance mechanismsBlood2026 Oct 1PMID 42821303
- Expanding the reach of menin inhibitorsNat Rev Cancer2026 OctPMID 42686827
More hematology trends
All specialties →Myelofibrosis treatment
JAK inhibitors and newer drugs in myelofibrosis.
Key point: Ruxolitinib-based combination regimens showed improved spleen and symptom responses with acceptable safety, with efficacy significantly influenced by prior JAK inhibitor exposure.
Post-transplant cyclophosphamide
Cyclophosphamide after stem cell transplant to prevent graft-versus-host disease.
Key point: Post-transplant cyclophosphamide appears to reduce graft-versus-host disease without increasing relapse or mortality in matched related donor transplantation for acute leukemia.
Haemophilia
Haemophilia and its newer treatments, including gene therapy and non-factor drugs.
Targeted therapy in CLL
BTK and BCL2 inhibitors in chronic lymphocytic leukaemia.
Key point: In CLL/SLL, treatment selection is tailored based on age, genetic risk and comorbidities, prioritizing zanubrutinib, acalabrutinib and venetoclax-based regimens.
Paroxysmal nocturnal haemoglobinuria
PNH and new oral complement inhibitors.
DOACs in heparin-induced thrombocytopenia
Studies of direct oral anticoagulants for the treatment of heparin-induced thrombocytopenia.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
revumenib[tiab] OR ziftomenib[tiab] OR "menin inhibitor*"[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.